NEXGEL, INC. (NXGL) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US65344E1073

Price
3.88 USD
Market cap
1.89 m USD
P/E (2025)
–
P/S (2025)
0.17
Dividend yield
0.00 %
Net margin
-26.27 %
Return on equity (ROE)
-67.28 %
Return on assets (ROA)
-28.68 %

NEXGEL, INC. financials

Fiscal year20242025
Revenue8.69 m USD11.42 m USD
Gross profit2.75 m USD4.51 m USD
Operating income-3.55 m USD-3.35 m USD
EBIT-3.38 m USD-2.86 m USD
Net income-3.28 m USD-3.00 m USD
Diluted EPS – continuing operations-0.50 USD-0.38 USD

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About NEXGEL, INC.

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.